Fresenius Total Current Liabilities from 2010 to 2024
| FMS Stock | USD 22.02 0.46 2.05% |
Total Current Liabilities | First Reported 1998-12-31 | Previous Quarter 5.9 B | Current Value 5.9 B | Quarterly Volatility 2.2 B |
Check Fresenius Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fresenius Medical's main balance sheet or income statement drivers, such as Interest Expense of 238.5 M, Total Revenue of 11.4 B or Gross Profit of 3.7 B, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0612 or PTB Ratio of 0.39. Fresenius financial statements analysis is a perfect complement when working with Fresenius Medical Valuation or Volatility modules.
Fresenius | Total Current Liabilities |
Latest Fresenius Medical's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Fresenius Medical Care over the last few years. Total Current Liabilities is an item on Fresenius Medical balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Fresenius Medical Care are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Fresenius Medical's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fresenius Medical's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Fresenius Total Current Liabilities Regression Statistics
| Arithmetic Mean | 4,584,916,986 | |
| Geometric Mean | 4,055,950,648 | |
| Coefficient Of Variation | 42.76 | |
| Mean Deviation | 1,690,976,879 | |
| Median | 4,789,663,479 | |
| Standard Deviation | 1,960,442,570 | |
| Sample Variance | 3843335.1T | |
| Range | 6.4B | |
| R-Value | 0.76 | |
| Mean Square Error | 1744346.9T | |
| R-Squared | 0.58 | |
| Significance | 0.001 | |
| Slope | 333,435,482 | |
| Total Sum of Squares | 53806691T |
Fresenius Total Current Liabilities History
About Fresenius Medical Financial Statements
Fresenius Medical shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Fresenius Medical investors may analyze each financial statement separately, they are all interrelated. The changes in Fresenius Medical's assets and liabilities, for example, are also reflected in the revenues and expenses on on Fresenius Medical's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 6.1 B | 3.6 B |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Fresenius Stock Analysis
When running Fresenius Medical's price analysis, check to measure Fresenius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fresenius Medical is operating at the current time. Most of Fresenius Medical's value examination focuses on studying past and present price action to predict the probability of Fresenius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fresenius Medical's price. Additionally, you may evaluate how the addition of Fresenius Medical to your portfolios can decrease your overall portfolio volatility.